DBT

Across TCGA pan-cancer cohorts, DBT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DBT data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher DBT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DBT expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where DBT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.840	0.531	.002	28	view →
CCRCC	OS	Median	IV	1.000	0.451	.016	6	view →
LUAD	OS	Median	II,III,IV	0.782	0.512	.021	5	view →
PDAC	DFS	Tertile	All	0.514	0.357	.044	2	view →
GBM	OS	Median	All	0.843	0.789	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DBT–LSCC (DFS)

Open the LSCC breakdown →